

March 30, 2015

As of March 27, Novozymes has purchased an accumulated 1,271,450 shares with a transaction value of DKK 400.1 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,125,000		353,307,066
23 March 2015	29,000	322.77	9,360,350
24 March 2015	28,500	323.36	9,215,783
25 March 2015	30,000	322.43	9,672,918
26 March 2015	29,000	314.07	9,107,986
27 March 2015	29,950	314.98	9,433,613
Accumulated under the program	1,271,450		400,097,716

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 3,785 B shares in the period from March 23 to March 27, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 5,244,877 treasury shares, corresponding to 1.7% of the stock capital. The total number of shares in the company is 313,000,000, including treasury shares.

Contact	information
contact	mornation

Investor Relations:		
Thomas Bomhoff (DK)	+45 3077 1226	<u>tsbm@novozymes.com</u>
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at <u>www.novozymes.com</u>.